Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
PSMA ligands bind prostate-specific membrane antigen (PSMA), a cell-surface glutamate carboxypeptidase. A complementary DNA encoding PSMA was cloned in 1993 from a human prostate carcinoma cell line. In 1996 the protein was shown to act as a hydrolase with the substrate and inhibitor profile of a neuropeptidase that cleaves N-acetylaspartylglutamate. The enzyme is also known as glutamate carboxypeptidase II and folate hydrolase 1 (FOLH1). Many compounds here carry a urea-linked glutamate motif that fits the active site, coupled to a chelator or labeling group. PSMA-11 carries a chelator for gallium-68, while PSMA-1007 and piflufolastat are fluorinated ligands. tert-Butyl-DCL is a protected inhibitor intermediate, and PSMA-ALB-56 adds an albumin-binding group.
Synonyms: PSMA-617; PSMA617 TFA; PSMA617 triflouroacetic acid salt
PSMA-617, also know as vipivotide tetraxetan. It is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer.
PSMA-ALB-56 is a PSMA-targeting radioligand that effectively binds to prostate-specific membrane antigen (PSMA) through a glutamate-urea binding motif coupled with an albumin-binding domain. This compound facilitates precise imaging and therapeutic applications in prostate cancer research by enhancing the retention of radiotracers in circulation. PSMA-ALB-56 is valuable for studies aimed at improving diagnostic and treatment protocols targeting PSMA-expressing tumors.
Synonyms: HBED-CC-PSMA
PSMA-11 is a small molecule ligand that specifically targets and inhibits prostate-specific membrane antigen (PSMA). This compound is utilized in the synthesis of 68Ga-PSMA-11, a positron emission tomography (PET) tracer employed in the imaging of advanced prostate cancer. Its capabilities in targeting PSMA make it a valuable reagent for cancer research and diagnostic applications, particularly in understanding prostate cancer progression and treatment response.
PSMA-1007 is a high-affinity ligand for the prostate-specific membrane antigen (PSMA). Labeled with 18F, this compound serves as an effective PET tracer for imaging prostate cancer, facilitating the detection and monitoring of malignancies. Additionally, PSMA-1007 is applicable in the synthesis and research of radionuclide-drug conjugates (RDCs), enhancing therapeutic strategies in oncology.
SC691 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA), a key target in prostate cancer research. This compound can be labeled with 68Ga(III), facilitating effective imaging and diagnosis in prostate cancer. SC691 is essential for advancing diagnostic methodologies and therapeutic strategies in the study of prostate malignancies.
Out of stock
All 3 sizes
Synonyms: PSMA I&T; PNT-2002
Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA). This compound is utilized in SPECT/CT imaging, providing valuable insights into the cellular profiles of triple-negative breast cancer and prostate cancer. Its application in radionuclide studies underscores its significance in cancer research and therapeutic development.
Synonyms: (OtBu)KuE(OtBu)2
Tert-Butyl-DCL is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA), a crucial target in prostate cancer research. Its inhibition of PSMA activity makes Tert-Butyl-DCL a valuable tool for studying the molecular mechanisms of prostate cancer progression and therapeutic interventions. This compound is ideal for applications in cancer biology and the development of PSMA-targeted therapies.
EC0652 is a potent PSMA imaging agent designed for SPECT imaging applications. It enables the detection and visualization of prostate-specific membrane antigen (PSMA) expression, making it a valuable tool in research focused on metastatic castration-resistant prostate cancer. This compound enhances the understanding of tumor biology and may aid in the development of targeted therapeutic strategies.
Out of stock
All 3 sizes
Flotufolastat is a prostate-specific membrane antigen (PSMA) modulator that serves as a radiodiagnostic agent for imaging prostate cancer. This compound is instrumental in enhancing the detection and characterization of prostate cancer lesions. Flotufolastat is valuable for research applications focused on prostate cancer and other malignancies associated with PSMA expression.
Out of stock
All 3 sizes
PSMA binder-1 is a potent ligand targeting Prostate-Specific Membrane Antigen (PSMA). It facilitates the synthesis of PSMA-targeting molecules, such as Ac-PSMA-trillium, providing a valuable tool for research in prostate cancer diagnosis and therapy. This compound is essential for studies focused on imaging and targeted treatment strategies aimed at PSMA-expressing tumors.
Synonyms: DCFPYL
Piflufolastat is a positron emission tomography (PET) imaging agent that specifically targets prostate-specific membrane antigen (PSMA). Labeled with fluorine-18, Piflufolastat F-18 serves as a diagnostic tool for the visualization of prostate cancer. Its application in molecular imaging enables enhanced detection and monitoring of prostate malignancies, supporting research and clinical decision-making in oncology.
PSMA-azide is a ligand targeting prostate-specific membrane antigen (PSMA). It effectively inhibits PSMA-dependent hydrolysis of N-acetylaspartylglutamic acid (NAAG) with an IC50 of 9 nM and a Ki of 1 nM, making it a valuable tool for studying PSMA-related pathways. Additionally, PSMA-azide features an azide moiety, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkynyl-containing molecules, facilitating various biochemical labeling and conjugation applications in research.
Glu-urea-Glu-NHS ester is an activated N-hydroxysuccinamide (NHS) ester of the Glu-urea-Glu compound. It serves as a versatile active intermediate in the synthesis of small-molecule inhibitors targeting prostate-specific membrane antigen (PSMA). This reagent is valuable for developing imaging agents, such as PSMAi-PEG conjugates, and enhancing the efficacy of targeted drug delivery systems in research applications.
GCPII-IN-1 is a potent inhibitor of the gene carboxypeptidase II (GCPII), also recognized as prostate-specific membrane antigen (PSMA), with a Ki value of 44.3 nM. This compound is primarily utilized in the research of prostate cancer, facilitating studies aimed at understanding tumor biology and developing potential therapeutic strategies. Its mechanism of action makes it a valuable tool for elucidating the role of GCPII in cancer progression.
GCPII-IN-1 TFA is a selective inhibitor of GCPII (glutamate carboxypeptidase II), also known as prostate-specific membrane antigen (PSMA), exhibiting a Ki value of 44.3 nM. This compound is instrumental in the investigation of prostate cancer, facilitating studies on the modulation of GCPII activity and its potential therapeutic applications in oncology. Researchers can utilize GCPII-IN-1 TFA to explore mechanisms of tumor growth and treatment resistance in prostate cancer models.
Prostate Specific Antigen Substrate is a fluorescent substrate utilized for the detection of enzymatic activity associated with prostate specific antigen (PSA). This reagent enables researchers to effectively measure PSA activity, aiding in the study of prostate cancer and other related conditions. Its application in various assays facilitates enhanced understanding of PSA's role in oncology research.
EC1169 is a PSMA-targeted maytansinoid conjugate that selectively binds to prostate-specific membrane antigen (PSMA). This compound delivers the cytotoxic maytansinoid B hydrazide payload directly to PSMA-positive tumor cells, demonstrating significant antitumor activity while sparing PSMA-negative cells. In preclinical models, EC1169 promotes complete recovery in mice with PSMA-positive tumors, exhibiting a favorable safety profile without inducing body weight loss or major organ damage. This reagent is valuable for research focused on prostate cancer and other PSMA-expressing malignancies.
Synonyms: LY4181530; PSMA-62
PNT2001 is a potent prostate-specific membrane antigen (PSMA) ligand, exhibiting an IC50 of 3.1 nM. This compound enhances cellular internalization, making it a valuable tool for targeting PSMA in prostate cancer research. Additionally, PNT2001 can be labeled with 177Lu and 225Ac, facilitating the development of radiolabeled therapies for prostate cancer treatment and diagnostic applications.
PSMA I&S is a key precursor for the synthesis of 99mTc-labeled PSMA-targeting ligands. This compound facilitates the generation of radiolabeled agents that selectively bind to the prostate-specific membrane antigen (PSMA), making it valuable for imaging and therapeutic applications in prostate cancer research. Its role in the development of novel radiopharmaceuticals enhances the ability to study PSMA expression in various biological contexts.
Synonyms: OTL-0078; OTL78
Zopocianine is a near-infrared optical probe targeting prostate-specific membrane antigen (PSMA). This compound selectively binds to PSMA expressed on the surface of cancer cells, facilitating receptor-mediated endocytosis and subsequent accumulation within acidic endosomes. Zopocianine is particularly effective for visualizing small tumors, primary prostate tumors, and locoregional metastases, making it a valuable tool in fluorescence-guided surgery for achieving negative tumor margins. Its applications are primarily in the field of prostate cancer research.
PSMA binder-2 is a potent ligand targeting Prostate-Specific Membrane Antigen (PSMA), facilitating the synthesis of Ac-PSMA-trillium, which exhibits enhanced binding and pharmacokinetic properties. This versatile compound can be modified with various radioactive isotopes for different applications; when labeled with 111In, it serves effectively as a DOTA chelating and imaging agent. Alternatively, when conjugated with 225Ac, it acts as a Macropa chelator, proving valuable for targeted radionuclide therapy (TRT) in the research of metastatic castration-resistant prostate cancer (mCRPC).
PSMA–DA1 is a radioactive inhibitor targeting Prostate-Specific Membrane Antigen (PSMA). It serves as a promising radiotheranostic agent for imaging and treating PSMA-expressing tumors. Its specificity for PSMA makes it a valuable tool in the research of prostate cancer diagnosis and therapy, enabling the development of effective targeted treatment strategies.
MIP-1072 is a selective inhibitor of prostate-specific membrane antigen (PSMA) that targets the enzyme's glutamate carboxypeptidase activity. With a Ki value of 4.6 nM, MIP-1072 demonstrates significant potency in inhibiting PSMA, making it a valuable tool in prostate cancer research. Its application is particularly relevant for studies focused on the role of PSMA in tumor progression and targeted therapies.
Synonyms: PRX-302
Topsalysin is a PSA-activated protoxin that functions as a pore-forming protein, specifically a synthetic proaerolysin fusion protein modified to target human prostate-specific antigen (PSA). It demonstrates significant tumor-suppressive effects in mouse models, making it a valuable tool for studying prostate cancer biology. Its unique mechanism allows for selective targeting of PSA-expressing tissues, providing insights into therapeutic approaches for prostate cancer treatment.
Out of stock
All 3 sizes
PSMA Ligand 1 is a potent PSMA ligand that exhibits an IC50 of 26.74 nM. This compound has been radiolabeled with [18F], making it a suitable candidate for use as a PET tracer in imaging studies. Its primary applications include aiding in the diagnosis and monitoring of prostate cancer, facilitating innovative research in oncology and molecular imaging.
Out of stock
All 3 sizes